

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**BEIJING TONG REN TANG CHINESE MEDICINE COMPANY LIMITED**

北京同仁堂國藥有限公司

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 3613)**

**VOLUNTARY ANNOUNCEMENT**

**RECEIVING THE CERTIFICATE OF REGISTRATION OF PROPRIETARY  
CHINESE MEDICINE**

This announcement is made by the board of directors (the “**Board**”) of Beijing Tong Ren Tang Chinese Medicine Company Limited (the “**Company**”) on a voluntary basis to inform its shareholders and potential investors of the latest business development about the Company.

The Board is pleased to announce that the Company recently received the Certificate of Registration of Proprietary Chinese Medicine (《中成藥註冊證明書》) issued by the Chinese Medicine Council of Hong Kong, allowing “Danggui Buxue Keli 【Tong Ren Tang】” (當歸補血顆粒【同仁堂】) to be sold in Hong Kong. The relevant details are as follows:

**I. Basic Information of the Medicine**

Name of the medicine: Danggui Buxue Keli 【Tong Ren Tang】 (當歸補血顆粒【同仁堂】)

Registrant and address: Beijing Tong Ren Tang Chinese Medicine Company Limited at 3 Dai King Street, Tai Po Industrial Estate, New Territories, Hong Kong

Registration number: HKC-18604

Certificate validity period: Until 25 April 2029

## **II. Other Related Information of the Medicine**

The function and main indications of the “Danggui Buxue Kelie 【Tong Ren Tang】” are to tonify qi and engender blood. It is used to treat fever caused by patterns of blood deficiency and floating yang. The symptoms include fever with a red complexion, vexation and thirst with a desire to drink. The pulses are surging, large, and deficient; however, forceless pulses appear whilst under heavy pressure. As of the date of this announcement, the Company has cumulatively invested approximately HK\$800 thousand (unaudited) in the research and development of “Danggui Buxue Kelie 【Tong Ren Tang】”. This product has not yet been launched for sales in market.

## **III. Impact on the Company and Risk Warning**

Upon obtaining the Certificate of Registration of Proprietary Chinese Medicine issued by the Chinese Medicine Council of Hong Kong, “Danggui Buxu Kelie 【Tong Ren Tang】” produced by the Company can be sold in Hong Kong, which is conducive to expanding the product lines of the Company and beneficial to the market expansion of the Company. The obtaining of the aforementioned certificate of registration will not have any material impact on the production, operation and performance of the Company for the time being. The sales of pharmaceutical products can be influenced by factors such as change in the policy environment, exchange rate fluctuations and market competition in the Hong Kong region.

**Shareholders and potential investors should exercise caution when dealing in the securities of the Company.**

By order of the Board  
**Beijing Tong Ren Tang**  
**Chinese Medicine Company Limited**  
**Gu Hai Ou**  
*Chairman*

Hong Kong, 30 April 2024

As at the date of this announcement, the composition of the Board is as follows:

***Executive Directors:***

Mr. Gu Hai Ou (*Chairman*)  
Mr. Chen Fei

***Non-executive Director:***

Ms. Feng Li

***Independent Non-executive Directors:***

Mr. Tsang Yok Sing, Jasper  
Mr. Xu Hong Xi  
Mr. Chan Ngai Chi